Is the shingles vaccine the secret to living longer and delaying dementia? Here’s what the science says.

Researchers have reported a growing number of studies that link receipt of the shingles vaccine Shingrix with lower rates of cardiovascular problems and a later onset of dementia. These findings have attracted attention because they suggest benefits beyond the vaccine’s role in preventing shingles.

The research to date points to associations between vaccination and improved longer-term outcomes, but investigators emphasize that the evidence is still developing. At present, the links reported in the literature do not by themselves establish a direct causal effect of the vaccine on heart disease or dementia risk.

Scientists are continuing to evaluate the strength and consistency of these associations and to explore biological explanations. Additional research — including replication of findings in different populations and studies designed to clarify mechanisms — will be needed to determine whether the observed relationships reflect a true protective effect of Shingrix.

For individuals making vaccination decisions, these emerging findings add to the discussion about potential benefits, but they do not replace established clinical guidance. People should consult their health care providers about whether Shingrix is appropriate for them and consider the totality of evidence as it evolves.